
By pursuing excellence in research, IBS has selected global leading scientists as directors of Centers. These directors are operating 31 Centers of which research proposals are evaluated superior in the IBS peer review process. The review is carried out by a Review Panel composed of independent and expert scientists from Korea and abroad. Directors choose the themes of their research and allocate funds accordingly. Generally, Centers operate projects with no fixed term for their duration as long as the quality of research is verified in evaluations. New Centers receive an initial evaluation five years after its launch, followed by three-year interval evaluations. IBS has been inviting top scientists from around the globe and providing them full support for their relocations. Young scientists also enjoy unique research opportunities to collaborate with world renowned scientists and to organize and operate their own research groups, broadening their professional expertise. IBS brings together outstanding talents throughout all career levels to grow and inspire each other through close collaborations.
我們正在追蹤 Institute For Basic Science (IBS) 的市場擴張
過去 90 日內有 1 個訊號。
Institute For Basic Science (IBS) 的國際擴張與競爭對手的比較
長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
Institute For Basic Science (IBS)你 | 0 | 0 | — | 0 | 0 |
目前並無招聘
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
IBS研究人員開發了'CDr17',一種可選擇性檢測M1巨噬細胞的螢光分子,有望改善類風濕性關節炎等自身免疫疾病的診斷。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Institute For Basic Science (IBS) 業務、市場及增長訊號的快速解答。
